• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

芪参益气滴丸联合常规西药治疗慢性心力衰竭的临床疗效与安全性：一项系统评价与Meta分析

Clinical Efficacy and Safety of Qishen Yiqi Dropping Pill Combined with Conventional Western Medicine in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis.

作者信息

Chen Lisheng, Wang Ruilin, Liu Honghong, Wei Shizhang, Jing Manyi, Wang Min, Zhao Yanling

机构信息

Department of Pharmacy, Fifth Medical Center, General Hospital of Chinese PLA, Beijing, China.

Department of Pharmacy, Hebei North University, Zhangjiakou, China.

出版信息

Evid Based Complement Alternat Med. 2021 Feb 2;2021:6612653. doi: 10.1155/2021/6612653. eCollection 2021.

DOI:10.1155/2021/6612653
PMID:33603818
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7872761/
Abstract

OBJECTIVE

The systematic review was designed to evaluate the safety and efficacy of Qishen Yiqi dropping pill combined with conventional Western medicine in the treatment of chronic heart failure (CHF).

METHODS

Relevant randomized controlled trials (RCTs) investigating the clinical efficacy of Qishen Yiqi dropping pill combined with conventional Western medicine in treating CHF were widely searched in electronic databases, including PubMed, Cochrane Library, EMBASE, CBM, CNKI, Read-show database, VIP database, and WanFang up to December 26, 2020. The methodological quality of each trial was assessed according to the Cochrane Reviewers' Handbook 5.0. Meta-analysis was performed by using Review Manager 5.3.

RESULTS

Twenty-one RCTs ( = 2162) that met the criteria were included in the review for the assessment of methodological quality. Meta-analysis showed that compared with the conventional Western medicine (control group), Qishen Yiqi dropping pill combined with conventional Western medicine (experience group) significantly improved clinical efficiency, left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular ejection fraction (LVEF), brain natriuretic peptide level (BNP), 6 min-walk distance (6-MWD), and adverse reactions.

CONCLUSION

Qishen Yiqi dropping pill combined with conventional Western medicine are better than conventional Western medicine alone to improve the indicators of patients with CHF, which provides a certain basis for the treatment of CHF.

摘要

目的

本系统评价旨在评估芪参益气滴丸联合传统西药治疗慢性心力衰竭（CHF）的安全性和有效性。

方法

在包括PubMed、Cochrane图书馆、EMBASE、中国生物医学文献数据库（CBM）、中国知网（CNKI）、维普资讯数据库、万方数据库在内的电子数据库中广泛检索截至2020年12月26日调查芪参益气滴丸联合传统西药治疗CHF临床疗效的相关随机对照试验（RCT）。根据Cochrane系统评价员手册5.0评估每个试验的方法学质量。使用RevMan 5.3进行Meta分析。

结果

纳入21项符合标准的RCT（n = 2162）进行方法学质量评估。Meta分析显示，与传统西药（对照组）相比，芪参益气滴丸联合传统西药（试验组）显著提高了临床有效率、左心室舒张末期内径（LVEDD）、左心室收缩末期内径（LVESD）、左心室射血分数（LVEF）、脑钠肽水平（BNP）、6分钟步行距离（6-MWD），并减少了不良反应。

结论

芪参益气滴丸联合传统西药在改善CHF患者指标方面优于单纯传统西药，为CHF的治疗提供了一定依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d7d/7872761/492006c1eb65/ECAM2021-6612653.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d7d/7872761/b810686a5f27/ECAM2021-6612653.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d7d/7872761/e6eefd350b7a/ECAM2021-6612653.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d7d/7872761/cbc9128074be/ECAM2021-6612653.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d7d/7872761/9dbb373d312d/ECAM2021-6612653.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d7d/7872761/848b5d137a93/ECAM2021-6612653.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d7d/7872761/5b2573c3e83d/ECAM2021-6612653.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d7d/7872761/c4a99d68e2b5/ECAM2021-6612653.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d7d/7872761/9f249024d1a9/ECAM2021-6612653.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d7d/7872761/047c8011c22d/ECAM2021-6612653.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d7d/7872761/492006c1eb65/ECAM2021-6612653.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d7d/7872761/b810686a5f27/ECAM2021-6612653.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d7d/7872761/e6eefd350b7a/ECAM2021-6612653.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d7d/7872761/cbc9128074be/ECAM2021-6612653.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d7d/7872761/9dbb373d312d/ECAM2021-6612653.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d7d/7872761/848b5d137a93/ECAM2021-6612653.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d7d/7872761/5b2573c3e83d/ECAM2021-6612653.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d7d/7872761/c4a99d68e2b5/ECAM2021-6612653.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d7d/7872761/9f249024d1a9/ECAM2021-6612653.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d7d/7872761/047c8011c22d/ECAM2021-6612653.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d7d/7872761/492006c1eb65/ECAM2021-6612653.010.jpg

相似文献

1
Clinical Efficacy and Safety of Qishen Yiqi Dropping Pill Combined with Conventional Western Medicine in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis.芪参益气滴丸联合常规西药治疗慢性心力衰竭的临床疗效与安全性：一项系统评价与Meta分析
Evid Based Complement Alternat Med. 2021 Feb 2;2021:6612653. doi: 10.1155/2021/6612653. eCollection 2021.
2
Efficacy and Safety of Qishen Yiqi Dripping Pill for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.芪参益气滴丸治疗射血分数保留的心力衰竭的疗效与安全性：一项系统评价和Meta分析
Front Pharmacol. 2021 Feb 9;11:626375. doi: 10.3389/fphar.2020.626375. eCollection 2020.
3
[Network Meta-analysis of Chinese patent medicines in treatment of chronic pulmonary heart disease].[中成药治疗慢性肺源性心脏病的网状Meta分析]
Zhongguo Zhong Yao Za Zhi. 2024 Jul;49(14):3936-3951. doi: 10.19540/j.cnki.cjcmm.20240318.501.
4
[Meta-analysis of effect of Qishen Yiqi Dripping Pills combined with Western medicine on adverse cardiovascular events and quality of life after percutaneous coronary intervention].[芪参益气滴丸联合西药对经皮冠状动脉介入治疗后不良心血管事件及生活质量影响的Meta分析]
Zhongguo Zhong Yao Za Zhi. 2021 Mar;46(6):1498-1510. doi: 10.19540/j.cnki.cjcmm.20200618.501.
5
[Network Meta-analysis of 11 Chinese patent medicines in treatment of dilated cardiomyopathy].11种治疗扩张型心肌病的中成药的网状Meta分析
Zhongguo Zhong Yao Za Zhi. 2023 Dec;48(24):6778-6797. doi: 10.19540/j.cnki.cjcmm.20230912.501.
6
Clinical efficacy and safety of adjunctive treatment of chronic ischemic heart failure with Qishen Yiqi dropping pills: a systematic review and meta-analysis.芪参益气滴丸辅助治疗慢性缺血性心力衰竭的临床疗效与安全性：一项系统评价与荟萃分析
Front Cardiovasc Med. 2023 Dec 18;10:1271608. doi: 10.3389/fcvm.2023.1271608. eCollection 2023.
7
The role of Qishen Yiqi dripping pills in treating chronic heart failure: An overview of systematic reviews and meta-analyses.芪参益气滴丸治疗慢性心力衰竭的作用：系统评价与Meta分析概述
Front Cardiovasc Med. 2022 Oct 24;9:1001072. doi: 10.3389/fcvm.2022.1001072. eCollection 2022.
8
[Routine western medicine treatment plus qishen yiqi dripping pill for treating patients with chronic heart failure: a systematic review of randomized control trials].[常规西药治疗联合芪参益气滴丸治疗慢性心力衰竭患者：随机对照试验的系统评价]
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013 Nov;33(11):1468-75.
9
[Network Meta-analysis of different Chinese medicine injections combined with conventional western medicine in treatment of acute heart failure].不同中药注射剂联合西医常规治疗急性心力衰竭的网状Meta分析
Zhongguo Zhong Yao Za Zhi. 2024 Jan;49(1):251-267. doi: 10.19540/j.cnki.cjcmm.20231016.501.
10
[Network Meta-analysis of six Chinese patent medicines for replenishing Qi and activating blood in treatment of chronic heart failure].六种益气活血中成药治疗慢性心力衰竭的网络Meta分析
Zhongguo Zhong Yao Za Zhi. 2022 Aug;47(15):4221-4237. doi: 10.19540/j.cnki.cjcmm.20220510.502.

引用本文的文献

1
Efficacy and safety of Qishen Yiqi dropping pills combined with modern medicine for coronary heart disease with ischemic heart failure: A systematic review and meta-analysis.芪参益气滴丸联合现代医学治疗冠心病合并缺血性心力衰竭的疗效及安全性的系统评价和 Meta 分析。
Medicine (Baltimore). 2024 Nov 1;103(44):e39927. doi: 10.1097/MD.0000000000039927.
2
Clinical efficacy and safety of adjunctive treatment of chronic ischemic heart failure with Qishen Yiqi dropping pills: a systematic review and meta-analysis.芪参益气滴丸辅助治疗慢性缺血性心力衰竭的临床疗效与安全性：一项系统评价与荟萃分析
Front Cardiovasc Med. 2023 Dec 18;10:1271608. doi: 10.3389/fcvm.2023.1271608. eCollection 2023.
3

本文引用的文献

1
Atorvastatin alleviates left ventricular remodeling in isoproterenol-induced chronic heart failure in rats by regulating the RhoA/Rho kinase signaling pathway.阿托伐他汀通过调节 RhoA/Rho 激酶信号通路缓解异丙肾上腺素诱导的慢性心力衰竭大鼠的左心室重构。
Pharmacol Rep. 2020 Aug;72(4):903-911. doi: 10.1007/s43440-020-00085-3. Epub 2020 Mar 6.
2
Effect of health literacy on quality of life among patients with chronic heart failure in China.健康素养对中国慢性心力衰竭患者生活质量的影响。
Qual Life Res. 2020 Feb;29(2):453-461. doi: 10.1007/s11136-019-02332-4. Epub 2019 Oct 18.
3
[Chinese guidelines for the diagnosis and treatment of heart failure 2018].
Comparative clinical-related outcomes of Chinese patent medicines for cardiac hypertrophy: A systematic review and network meta-analysis of randomized clinical trials.
治疗心脏肥大的中成药的比较临床相关结局：一项随机临床试验的系统评价和网状Meta分析
Front Pharmacol. 2023 Jan 23;14:963099. doi: 10.3389/fphar.2023.963099. eCollection 2023.
4
Bibliometric analysis of traditional Chinese medicine research on heart failure in the 21st century based on the WOS database.基于WOS数据库的21世纪中医治疗心力衰竭研究的文献计量分析
Heliyon. 2023 Jan 4;9(1):e12770. doi: 10.1016/j.heliyon.2022.e12770. eCollection 2023 Jan.
5
, : Toward the modernization of traditional Chinese medicine.迈向中医药现代化。
Front Neurosci. 2022 Nov 10;16:1057817. doi: 10.3389/fnins.2022.1057817. eCollection 2022.
6
Integrated network pharmacology and metabolomics to reveal the mechanism of QiShenYiQi Dripping Pills (T101) against cardiac structural and functional abnormalities.整合网络药理学和代谢组学以揭示芪参益气滴丸（T101）对抗心脏结构和功能异常的机制。
Front Pharmacol. 2022 Oct 24;13:1017433. doi: 10.3389/fphar.2022.1017433. eCollection 2022.
7
The role of Qishen Yiqi dripping pills in treating chronic heart failure: An overview of systematic reviews and meta-analyses.芪参益气滴丸治疗慢性心力衰竭的作用：系统评价与Meta分析概述
Front Cardiovasc Med. 2022 Oct 24;9:1001072. doi: 10.3389/fcvm.2022.1001072. eCollection 2022.
8
Effect of Chaihu Shugan Pills on the Pharmacokinetics of Duloxetine and its Metabolite 4-Hydroxyduloxetine in Beagle Dogs: A Herb-Drug Interaction Study.柴胡疏肝丸对比格犬度洛西汀及其代谢物4-羟基度洛西汀药代动力学的影响：一项药物相互作用研究。
Evid Based Complement Alternat Med. 2022 Aug 17;2022:2350560. doi: 10.1155/2022/2350560. eCollection 2022.
《中国心力衰竭诊断和治疗指南2018》
Zhonghua Xin Xue Guan Bing Za Zhi. 2018 Oct 24;46(10):760-789. doi: 10.3760/cma.j.issn.0253-3758.2018.10.004.
4
Huangqi injection in the treatment of chronic heart failure: A systematic review and meta-analysis.黄芪注射液治疗慢性心力衰竭：一项系统评价与Meta分析
Medicine (Baltimore). 2017 Sep;96(39):e8167. doi: 10.1097/MD.0000000000008167.
5
Specificity of B-Type Natriuretic Peptide Assays: Cross-Reactivity with Different BNP, NT-proBNP, and proBNP Peptides.B型利钠肽检测的特异性：与不同的B型利钠肽、N末端B型利钠肽原及B型利钠肽原肽的交叉反应性
Clin Chem. 2017 Jan;63(1):351-358. doi: 10.1373/clinchem.2016.263749. Epub 2016 Nov 15.
6
Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging catabolism study.运动训练可减轻慢性心力衰竭患者骨骼肌中 MuRF-1 的表达，与年龄无关：随机莱比锡慢性心力衰竭和衰老代谢研究中的运动干预。
Circulation. 2012 Jun 5;125(22):2716-27. doi: 10.1161/CIRCULATIONAHA.111.047381. Epub 2012 May 7.
7
Attenuating effect of post-treatment with QiShen YiQi Pills on myocardial fibrosis in rat cardiac hypertrophy.芪参益气滴丸对心肌肥厚大鼠心肌纤维化的影响。
Clin Hemorheol Microcirc. 2012;51(3):177-91. doi: 10.3233/CH-2011-1523.
8
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.Cochrane 协作网评估随机试验偏倚风险的工具。
BMJ. 2011 Oct 18;343:d5928. doi: 10.1136/bmj.d5928.
9
[Guidelines for the diagnosis and management of chronic heart failure].[慢性心力衰竭诊断与管理指南]
Zhonghua Xin Xue Guan Bing Za Zhi. 2007 Dec;35(12):1076-95.